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Background: We have previously found that atorvastatin decreases liver injury markers 
in patients with nonalcoholic steatohepatitis. However, how atorvastatin treatment 
ameliorates the disease activity in nonalcoholic steatohepatitis patients remains 
unknown. Aims: We examined here which anthropometric, metabolic and inflammatory 
variables were improved and related with amelioration of disease activity in 
atorvastatin-treated nonalcoholic steatohepatitis patients.  Methods:  Forty­two 
biopsy­proven  nonalcoholic steatohepatitis  patients  with  dyslipidemia  were  enrolled. 
Patients were treated with atorvastatin (10 mg/day) for 12 months. Results: Atorvastatin 
significantly decreased liver transaminase, ­glutamyl  transpeptidase,  low-density 
lipoprotein-cholesterol, triglycerides, type IV collagen, and tumor necrosis factor- 
levels, while it increased adiponectin and high-density lipoprotein-cholesterol. 
Atorvastatin improved nonalcoholic fatty liver disease activity score and increased liver 
to spleen density ratio. Multiple  stepwise  regression  analysis  revealed  that  ­glutamyl 
transpeptidase, tumor necrosis factor- and liver to spleen density ratio (inversely) were 
independently associated with nonalcoholic fatty liver disease activity score. Aspartate 
aminotransferase,  low­density  lipoprotein­cholesterol  and  nonalcoholic fatty liver 
disease  activity  score  were  independent  determinants  of  decreased  liver to spleen 
density  ratio.  Conclusion:  The present study suggests that atorvastatin improves the 
disease activity of nonalcoholic steatohepatitis partly via its tumor necrosis factor- 
-lowering property. 
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Introduction 
Nonalcoholic  fatty  liver  disease  (NAFLD)  is  among  the  most  common  causes  of 
chronic liver disease in the western world and is histologically categorized into steatosis 
and  steatohepatitis  [1].  The  latter  histological  entity,  nonalcoholic  steatohepatitis 
(NASH) may be a potentially progressive hepatic disorder that can lead to liver cirrhosis 
and  hepatocellular  carcinoma  [2].  Insulin  resistance  increases  visceral  adipocyte 
lipolysis  and  subsequently  releases  free  fatty  acids  into  the  portal  circulation,  where 
they  are  rapidly  translocated  to  the  liver,  thereby  eliciting  hepatic  steatosis  [2].  Fatty 
acids  stimulate  reactive  oxygen  species  generation  in  the  liver,  promoting  the  disease 
progression to NASH by enhancing both lipid peroxidation and inflammatory cytokine 
production  [2].  Necro­inflammatory  component  of  NASH  could  be  modulated  by 
various factors that stimulate the biological activity of tumor necrosis factor- (TNF-) 
[3].  Further,  pentoxifylline, an inhibitor of TNF-, is reported to ameliorate insulin 
resistance and decrease liver transaminase in patients with NASH [4­6]. These 
observations  suggest  that  inflammatory cytokine­evoked  insulin  resistance may be  the 
most consistent pathogenic factor of NASH.   
We, along with others, have recently found that statins such as atorvastatin, one of 
the most widely used drugs for  the  treatment of hypercholesterolemia, are effective  in 
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patients  with  NASH  with  dyslipidemia;  atorvastatin  not  only  decreases  liver 
transaminase,  but  also  suppresses  hepatic  steatosis  in  these  patients  [7­12]. However, 
how  atorvastatin  could  ameliorate  NASH  remains  unknown. We  first  examined  here 
whether  atorvastain  treatment  significantly  improved  anthropometric,  metabolic  and 
inflammatory variables, which might be related with disease activity of NASH, and then 





50.5±12.7 years old) were enrolled in the present study. All patients were negative for 
serology and viral hepatitis, and had no history of liver diseases. Current and past daily 
alcohol intake of the subjects was less than 20 g per week. Further, we excluded any 
patients  with drug-induced hepatitis, autoimmune hepatitis, primary biliary cirrhosis, 
hemochromatosis, Wilson's disease and biliary obstruction. Fourteen subjects were type 
2 diabetes mellitus (DM), 13 impaired glucose tolerance (IGT) and 19 essential 




type  1  receptor  blockers  N=6  (telmisartan  N=1),  calcium  channel  blockers  N=12). 
Within  a  couple  of  weeks  after  the  first  liver  biopsies,  all  patients  started  taking 
atorvastatin  (10  mg  once  daily).  After  12  month­atorvastain  therapy,  post-treatment 
second liver biopsies were performed. Then computed tomography (CT) scanning was 
performed for quantitatively evaluating fat content in the liver. Liver fat content was 
shown as CT density ratio of liver to spleen (L/S density ratio) as described previously 
[13]. During the study period, subjects were instructed to improve their life styles and to 
continue  taking  the  same  dose  of  any  concomitant  drugs.  Nobody  received  other 
anti­dyslipidemic  agents  than  atorvastatin. Informed  consent  was  obtained  from  all 




determinations  of  lipid  profiles;  total  cholesterol  (T­Chol),  LDL­cholesterol  (LDL­C), 
triglycerides  (TG),  and  HDL­cholesterol  (HDL­C),  fasting  plasma  glucose  (FPG), 
fasting plasma insulin (IRI), glycated hemoglobin (HbA1c), aspartate aminotransferase 




previously  [10,11]. Insulin resistance was estimated using the homeostasis model 
assessment of insulin resistance (HOMA-IR). HOMA-IR index was calculated from the 
values of FPG (mg/dL) and IRI (U/ml) using the following formula [(FPG  IRI)/405]. 
Patients enrolled in this study underwent a percutaneous liver biopsy under 
ultrasonic guidance before and after atorvastatin treatment when the informed consent 
was obtained. All the specimens were examined by an experienced pathologist who was 
unaware of the clinical and biochemical data of the patients. All cases showed 
macrovesicular steatosis affecting at least 5% of hepatocytes and were classified as 
either steatosis or steatohepatitis. In addition to steatosis, the minimum criteria for the 
diagnosis of steatohepatitis included the presence of lobular inflammation and either 
ballooning cells or perisinusoidal/pericellular fibrosis in zone 3 of the hepatic acinus as 
described previously [14]. NAS was calculated as the unweighted sum of the scores for 
steatosis, lobular inflammation, and ballooning as reported by Kleiner et al [15]. 
A correlation between NAS, L/S density ration, TNF-, and other clinical variables 
was determined by a linear regression analysis. To determine independent determinants 
of NAS, L/S density ration and TNF-, multiple stepwise regression analysis was 
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performed. Statistical significance was defined as p<0.05. All statistical analyses were 
performed with the use of the SPSS system (SPSS Japan Inc., IBM company, Tokyo, 
Japan). Statistical analysis was done on all the data including both pre- and 
post-treatments of atorvastatin.  
 
Results 
Clinical  and  laboratory  variables  of  all  subjects  at  baseline  and  after  atorvastatin 
treatment are  shown  in Table 1. Atorvastatin  significantly decreased BMI, AST, ALT, 
­GTP,  T­Chol,  TG,  LDL­C,  FPG,  type  IV  collagen  and  TNF­,  while  it  increased 
albumin, HDL­C  and  adiponectin. Although  atorvastatin  did  not  affect  HOMA­IR,  it 
significantly improved NAS and increased L/S density ratio. When the data of male and 
female  were  analyzed  separately,  there  were  some  differences  in  atorvastatin  effects 
between  them.  As  shown  in  Table  2,  atorvastatin  significantly  decreased  FPG  and 















NAS,  adiponectin  (inversely)  and  L/S  density  ratio  (inversely)  were  correlated  with 
TNF­ in univariate analysis (Table 5). BMI, DM medication or HT medication was not 





TNF­  and  L/S  density  ratio  (inversely),  but  not  LDL­C  level  in  univariate  analysis 
(Table  3).  Further,  multiple  stepwise  regression  analysis  showed  that  ­GTP,  TNF­, 
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and  L/S  density  ratio  (inversely)  were  independently  correlated  with  NAS.  These 
observations  suggest  that  although  cholesterol  level  was  associated  with  L/S  density 
ratio (Table 4), atorvastatin treatment for 12 months could suppress the disease activity 
of NASH  in  a  cholesterol  lowering­independent  manner.  In this study, although 
atorvastatin did not affect insulin sensitivity measured by HOMA-IR index, it improved 
adipocytokin profiles in NASH patients. Further, TNF­,  but  not  adiponectin,  was 
independently  associated  with  NAS.  These  findings  suggest  that TNF­–reducing 
property of atorvastatin rather than its adiponectin-elevating and insulin sensitizing 
effects may exert beneficial effects on NASH in our patients. Jarrar et al. reported that 
among various adipocytokins, TNF­ was the only independent predictor of fibrosis in 
NASH [16], thus further supporting the pathological role of TNF­ in the progression 
of NASH.  





or  TNF­  in  univariate  analyses  (Tables  3­5).  It  is  in  sharp  contrast  with  previous 
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well­done studies on NASH showing that over weight and obesity are the mile stone in 
the  pathogenesis  of  NASH  and  life  style  changes  including  weight  loss  and  dietary 
changes are considered first­line therapeutic option [17,18]. The present study included 
only NASH patients with dyslipidemia and all patients were  treated with atorvastatin. 
Therefore,  the  low  number  of  patients  and  the  selection  bias  of  this  study may  have 
influenced the results.  In the present study, DM medication or HT medication was not 
associated with NAS, L/S  density  ratio  or TNF­  (Tables  3­5).  So,  it  is  unlikely  that 
DM  medication  or  HT  medication  could  be  associated  with  TNF­  reduction  and 
improvement of NASH in our subjects. 
In this study, the magnitude of LDL-C reduction obtained by atorvastatin treatment 
was independently correlated with that of increase in L/S density ratio (Table 4). 
Therefore, it is probable that atorvastain not only blocks hepatic steatosis by reducing 
LDL-C levels, but also inhibits the disease progression of NASH partly via the 
reduction of TNF­.  
We have previously shown that advanced glycation end products (AGEs) evoke 
inflammatory and proliferative reactions in hepatic stellate cells, thus participating in 
the progression of NASH [19]. Further, serum levels of AGEs were significantly 
elevated in NASH patients compared with simple steatosis [14], and atrovastatin 
 12 
treatment decreased circulating levels of AGEs in NASH subjects with dyslipidemia 
[11]. Oxidative stress participates in the formation of AGEs, and hydroxyl metabolites 
of  atorvastatin  have  been  shown  to  have  anti­oxidative  properties  [20].  Given the 
present findings that HbA1c  level  was  unchanged  by  the  atorvastatin  treatment, 
atorvastatin may reduce serum AGEs levels via its anti­oxidative property, which could 







This  study  is  not  a  randomized  study.  Thus without  a  control  group  (NASH without 
dyslipemia or not  treated with  statin), many  factors may have confounded  the  results. 
However, in this study, multiple stepwise regression analysis utilizing all the data (both 
before  and  after  treatments)  revealed  that  ­GTP,  TNF­,  and  L/S  density  ratio 
(inversely) were independently correlated with NAS, while AST, LDL­C and NAS were 










Only  one  subject  received  telmisartan,  an  angiotensin  II  type  1  receptor  blocker 
with  peroxisome  proliferator­activated  receptor­gamma­modulating  activity  [23]. 
Therefore, we could not evaluate here the exact role of telmisartan in TNF­ reduction. 
Further, lipopolysaccharides (LPS) may be associated with NASH and induce increased 
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Table 1. C linical variables of all subjects before and after atorvastatin 
treatment 
 
Characteristics before treatment after treatment p-value 
Age (years) 50.0±12.7   
Number (male number) 42 (28)   
Body mass index (kg/m2) 27.2±2.9 26.3±2.7 p<0.01 
AST (IU/L) 48.0±26.7 33.0±18.4 p<0.01 
ALT (IU/L) 89.0±61.9 56.6±52.3 p<0.01 
-GTP (IU/L) 90.4±89.9 65.1±49.9 p<0.05 
Total-bilirubin (mg/dL) 0.9±0.3 0.9±0.3 0.765 
Direct-bilirubin (mg/dL) 0.4±1.5 0.2±0.3 0.412 
Albumin (g/dL) 4.6±0.3 4.8±0.3 p<0.01 
T-Chol (mg/dl) 233.9±35.0 177.0±35.5 p<0.01 
TG (mg/dl) 206.8±114.8 150.1±73.1 p<0.01 
HDL-C (mg/dl) 48.0±12.5 54.1±11.9 p<0.01 
LDL-C (mg/dl) 144.5±29.2 92.9±30.8 p<0.01 
FPG (mg/dl)      107.9±14.9 104.4±17.3 p<0.05 
HbA1c (%)         6.2±0.8 6.1±0.6 0.469 
IRI (U/mL)     12.9±6.7 13.1±7.1 0.560 
HOMA-IR      3.2±2.0 3.4±1.9 0.534 
NAS 3.9±1.0 3.0±0.9 p<0.01 
Adiponectin (g/mL) 5.5±2.3 6.4±2.8 p<0.01 
TNF- (pg/mL) 17.1±5.8 11.1±7.8 p<0.01 
Type IV collagen (ng/mL) 4.2±1.0 3.8±0.8 p<0.05 
Ferritin (ng/mL) 221.1±172.0 186.6±174.1 0.085 
L/S density ratio 0.5±0.3 0.9±0.2 p<0.01 
Number (DM/IGT/HT) 14/13/19 14/13/19 - 
DM medication 4 4 - 
HT medication 14 14 - 
Data are shown as mean±standard deviation, unless otherwise indicated. 
AST;  aspartate  aminotransferase,  ALT;  alanine  aminotransferase,  ­GTP;­glutamyl 
transpeptidase,  T­Chol;  total  cholesterol,  TG;  triglycerides,  HDL­C;  high­density 
Table(s)
 2 
lipoprotein­cholesterol,  LDL­C;  low­density  lipoprotein­cholesterol,  FPG;  fasting 
plasma glucose, HbA1c; glycated hemoglobin, IRI; fasting plasma insulin, HOMA­IR; 
homeostasis model assessment of insulin resistance, NAS; nonalcoholic fatty liver 
disease activity score, TNF-; tumor necrosis factor-, L/S; liver to spleen, DM; diabetes 
mellitus, IGT; impaired glucose tolerance, HT; hypertension. 
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Table 2. C linical variables of male and female before and after 
atorvastatin treatment 
 











Age (years) 47.8±12.4   54.4±12.6   
Number (male number) 28   14   
Body mass index (kg/m2) 27.2±3.0 26.3±2.8 p<0.01 27.2±2.9 26.1±2.6 p<0.01 
AST (IU/L) 45.9±21.7 34.9±20.0 p<0.01 52.2±35.2 29.1±14.8 p<0.05 
ALT (IU/L) 89.3±59.1 63.9±60.0 p<0.01 88.5±69.4 42.1±28.2 p<0.05 
-GTP (IU/L) 81.3±77.4 66.3±52.8 0.070 108.4±111.9 62.6±45.3 0.068 
Total-bilirubin (mg/dL) 0.9±0.4 0.9±0.3 0.778 0.8±0.2 0.9±0.3 0.212 
Direct-bilirubin (mg/dL) 0.5±1.8 0.2±0.4 0.403 0.1±0.1 0.2±0.1 0.500 
Albumin (g/dL) 4.6±0.3 4.8±0.3 p<0.01 4.5±0.2 4.8±0.4 p<0.01 
T-Chol (mg/dl) 228.8±34.0 166.5±31.7 p<0.01 244.0±36.1 198.0±34.3 p<0.01 
TG (mg/dl) 214.1±127.9 167.9±81.7 p<0.05 192.3±85.2 114.6±31.0 p<0.01 
HDL-C (mg/dl) 44.8±9.7 49.8±9.8 p<0.01 54.5±15.2 62.8±11.3 0.087 
LDL-C (mg/dl) 141.2±31.6 83.1±26.8 p<0.01 151.0±23.5 112.4±29.8 p<0.01 
FPG (mg/dl)      104.4±11.1 100.6±15.0 p<0.05 114.8±19.2 112.0±19.5 0.483 
HbA1c (%)         5.5±0.5 5.6±0.6 0.125 6.4±0.8 6.0±0.6 p<0.05 
IRI (U/mL)     12.7±5.5 14.8±7.4 0.117 13.4±9.0 8.9±4.4 0.325 
HOMA-IR      3.0±1.3 3.7±2.0 0.088 3.6±3.0 2.5±1.5 0.572 
NAS 3.9±1.0 2.9±0.9 p<0.01 4.0±1.2 3.1±0.9 p<0.05 
Adiponectin (g/mL) 4.8±1.5 6.0±2.5 p<0.01 6.8±3.0 7.6±3.3 0.092 
TNF- (pg/mL) 17.0±5.4 10.1±7.6 p<0.01 18.7±5.2 13.2±7.9 p<0.05 
Type IV collagen (ng/mL) 4.0±0.8 3.8±0.7 0.134 4.5±1.3 3.8±1.1 p<0.05 
Ferritin (ng/mL) 253.2±187.1 218.0±192.1 0.271 151.9±110.7 106.9±76.1 p<0.05 
L/S density ratio 0.6±0.3 1.0±0.2 p<0.01 0.5±0.3 0.9±0.3 p<0.01 
Number (DM/IGT/HT) 5/9/10 5/9/10 - 9/4/9 9/4/9 - 
DM medication 2 2 - 2 2 - 
HT medication 6 6 - 8 8 - 
Data are shown as mean±standard deviation, unless otherwise indicated. 
AST;  aspartate  aminotransferase,  ALT;  alanine  aminotransferase,  ­GTP;­glutamyl 
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transpeptidase,  T­Chol;  total  cholesterol,  TG;  triglycerides,  HDL­C;  high­density 
lipoprotein­cholesterol,  LDL­C;  low­density  lipoprotein­cholesterol,  FPG;  fasting 
plasma glucose, HbA1c; glycated hemoglobin, IRI; fasting plasma insulin, HOMA­IR; 
homeostasis model assessment of insulin resistance, NAS; nonalcoholic fatty liver 
disease activity score, TNF-; tumor necrosis factor-, L/S; liver to spleen, DM; diabetes 






 Univariate* Multivariate+ 
Factors  P  P 
Body mass index (kg/m2) 0.140 0.268   
AST (IU/L) 0.359 P<0.01   
ALT (IU/L) 0.326 P<0.01   
-GTP (IU/L) 0.297 P<0.05 0.255 P<0.05 
Total-bilirubin (mg/dL) -0.022 0.861   
Direct-bilirubin (mg/dL) -0.053 0.676   
Albumin (g/dL) -0.008 0.949   
T-Chol (mg/dl) 0.174 0.168   
TG (mg/dl) 0.050 0.694   
HDL-C (mg/dl) 0.051 0.688   
LDL-C (mg/dl) 0.153 0.226   
FPG (mg/dl)      0.062 0.625   
HbA1c (%)         0.049 0.703   
IRI (U/mL)     0.138 0.305   
HOMA-IR      0.188 0.169   
Adiponectin (g/mL) -0.272 P<0.05   
TNF- (pg/mL) 0.389 P<0.01 0.310 P<0.01 
Type IV collagen (ng/mL) 0.238 0.059   
Ferritin (ng/mL) 0.132 0.305   
L/S density ratio -0.549 P<0.01 -0.404 P<0.01 
DM -0.120 0.346   
HT 0.016 0.898   
DM medication -0.123 0.333   





AST;  aspartate  aminotransferase,  ALT;  alanine  aminotransferase,  ­GTP;­glutamyl 
transpeptidase,  T­Chol;  total  cholesterol,  TG;  triglycerides,  HDL­C;  high­density 
 6 
lipoprotein­cholesterol,  LDL­C;  low­density  lipoprotein­cholesterol,  FPG;  fasting 
plasma glucose, HbA1c; glycated hemoglobin, IRI; fasting plasma insulin, HOMA­IR; 
homeostasis model assessment of insulin resistance, NAS; nonalcoholic fatty liver 
disease activity score, TNF-; tumor necrosis factor-, L/S; liver to spleen, DM; diabetes 






 Univariate* Multivariate+ 
Factors  P  P 
Body mass index (kg/m2) -0.181 0.113   
AST (IU/L) -0.438 P<0.01 -0.192 P<0.05 
ALT (IU/L) -0.371 P<0.01   
-GTP (IU/L) -0.185 0.105   
Total-bilirubin (mg/dL) 0.034 0.769   
Direct-bilirubin (mg/dL) -0.139 0.225   
Albumin (g/dL) 0.171 0.135   
T-Chol (mg/dl) -0.485 P<0.01   
TG (mg/dl) -0.072 0.534   
HDL-C (mg/dl) 0.112 0.330   
LDL-C (mg/dl) -0.549 P<0.01 -0.439 P<0.01 
FPG (mg/dl)      0.064 0.578   
HbA1c (%)         0.138 0.229   
IRI (U/mL)     0.029 0.820   
HOMA-IR      0.069 0.599   
NAS -0.549 P<0.01 -0.422 P<0.01 
Adiponectin (g/mL) 0.137 0.245   
TNF- (pg/mL) -0.340 P<0.01   
Type IV collagen (ng/mL) -0.101 0.381   
Ferritin (ng/mL) 0.013 0.909   
DM 0.025 0.825   
HT 0.244 P<0.05   
DM medication   0.108 0.346   





AST;  aspartate  aminotransferase,  ALT;  alanine  aminotransferase,  ­GTP;­glutamyl 
transpeptidase,  T­Chol;  total  cholesterol,  TG;  triglycerides,  HDL­C;  high­density 
 8 
lipoprotein­cholesterol,  LDL­C;  low­density  lipoprotein­cholesterol,  FPG;  fasting 
plasma glucose, HbA1c; glycated hemoglobin, IRI; fasting plasma insulin, HOMA­IR; 
homeostasis model assessment of insulin resistance, NAS; nonalcoholic fatty liver 
disease activity score, TNF-; tumor necrosis factor-, L/S; liver to spleen, DM; diabetes 






 Univariate* Multivariate+ 
Factors  P  P 
Body mass index (kg/m2) 0.006 0.959   
AST (IU/L) 0.146 0.191   
ALT (IU/L) 0.068 0.543   
-GTP (IU/L) 0.115 0.305   
Total-bilirubin (mg/dL) 0.148 0.185   
Direct-bilirubin (mg/dL) -0.049 0.660   
Albumin (g/dL) -0.186 0.095   
T-Chol (mg/dl) 0.252 p＜0.05   
TG (mg/dl) 0.136 0.223   
HDL-C (mg/dl) -0.165 0.139   
LDL-C (mg/dl) 0.269 p＜0.05   
FPG (mg/dl)      0.171 0.124   
HbA1c (%)         0.214 0.054   
IRI (U/mL)     0.034 0.785   
HOMA-IR      0.017 0.896   
NAS 0.389 p＜0.01 0.351 p<0.01 
Adiponectin (g/mL) -0.283 p＜0.05 -0.306 p<0.05 
Type IV collagen (ng/mL) 0.189 0.088   
Ferritin (ng/mL) -0.050 0.662   
L/S density ratio -0.340 p＜0.01   
DM 0.170 0.126   
HT -0.099 0.374   
DM medication 0.142 0.203   





AST;  aspartate  aminotransferase,  ALT;  alanine  aminotransferase,  ­GTP;­glutamyl 
transpeptidase,  T­Chol;  total  cholesterol,  TG;  triglycerides,  HDL­C;  high­density 
 10 
lipoprotein­cholesterol,  LDL­C;  low­density  lipoprotein­cholesterol,  FPG;  fasting 
plasma glucose, HbA1c; glycated hemoglobin, IRI; fasting plasma insulin, HOMA­IR; 
homeostasis model assessment of insulin resistance, NAS; nonalcoholic fatty liver 
disease activity score, TNF-; tumor necrosis factor-, L/S; liver to spleen, DM; diabetes 
mellitus, HT; hypertension. 
 
